J. Gonzalo Ocejo-Vinyals

Dr. J. Gonzalo Ocejo-Vinyals

Laboratorio de Histocompatibilidad e Inmunogenética, Servicio de Inmunología. Hospital Universitario Marqués de Valdecilla
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Cytokine
Verified
Journal Article
Closed access
J. Gonzalo Ocejo-VinyalsJ. Gonzalo Ocejo-Vinyals
J. Gonzalo Ocejo-Vinyals
EMElena Puente de Mateo
Elena Puente de Mateo
MHMaría Ángeles Hoz
María Ángeles Hoz
JAJosé Luis Arroyo
José Luis Arroyo
RARamón Agüero
Ramón Agüero
MFM. Carmen Fariñas
M. Carmen Fariñas

14 April 2015 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
Raquel López MejíasRaquel López Mejías
Raquel López Mejías
FGFernanda Genre
Fernanda Genre
BPBelén Sevilla Pérez
Belén Sevilla Pérez
Santos CastañedaSantos Castañeda
Santos Castañeda
NONorberto Ortego-Centeno
Norberto Ortego-Centeno
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
Introduction: A study was conducted to determine whether the human leukocyte antigen (HLA) B alleles are implicated in the susceptibility to Henoch-Schönlein purpura (HSP) in the largest series of Caucasian HSP patients ever assessed for genetic studies. Methods: The study population was composed of 349 Spanish patients diagnosed with HSP fulfilling the American College of Rheumatology and the Michel et al. classification criteria, and 335 sex and ethnically matched controls. HLA-B phenotypes were determined by sequencing-based typing (SBT) and analyzed by chi-square or Fisher exact test. Results: A statistically significant increase of HLA-B*41:02 allele in HSP patients when compared with controls was found (8.3% versus 1.5% respectively; P = 0.0001; OR (odds ratio) =5.76 [2.15-19.3]). These results remained statistically significant after adjusting for Bonferroni correction (P = 0.0028). An internal validation also confirmed the susceptibility effect on HSP associated with HLA-B*41:02 (OR = 5.70 [1.98-16.44]). Since a former study described an association between HLA-DRB1*01:03 and HSP susceptibility, we also evaluated the implication of HLA-B*41:02 independently of HLA-DRB1*01:03. Interestingly, the association remained statistically significant (P = 0.0004, OR = 4.97 [1.8-16.9]). No HLA-B association with specific HSP clinical features was found. Conclusions: Our study indicates that HLA-B*41:02 is associated with the susceptibility to HSP in Spanish patients irrespective of HLA-DRB1 status.

Verified
Journal Article
Open access
PDF file
VCVerónics Pulito Cueto
Verónics Pulito Cueto
FGFernanda Genre
Fernanda Genre
Raquel López MejíasRaquel López Mejías
Raquel López Mejías
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
DFDavid Iturbe Fernández
David Iturbe Fernández
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
The aim of this study was to determine the role of endothelin-1 (ET-1), a molecule involved in multiple vascular and fibrosing abnormalities, as a biomarker of interstitial lung disease (ILD), as well as its use for the differential diagnosis between idiopathic pulmonary fibrosis (IPF) and ILD associated with autoimmune diseases (AD-ILD), using a large and well-defined cohort of patients with ILD. A total of 112 patients with IPF, 91 patients with AD-ILD (28 rheumatoid arthritis (RA), 26 systemic sclerosis, 20 idiopathic inflammatory myositis and 17 interstitial pneumonia with autoimmune features) and 44 healthy controls were included. ET-1 serum levels were determined by enzyme-linked immunosorbent assay. A significant increase in ET-1 levels was found in patients with IPF compared to controls. Likewise, AD-ILD patients also showed higher ET-1 levels than controls when the whole cohort was stratified by the type of AD. Similar ET-1 levels were found in IPF and AD-ILD patients, regardless of the underlying AD. Interestingly, increased ET-1 levels were correlated with worse lung function in IPF and RA-ILD patients. Our study supports that serum ET-1 may be useful as a biomarker of ILD, although it could not help in the differential diagnosis between IPF and AD-ILD. Moreover, ET-1 levels may be associated with ILD severity.

1 July 2019 in Human Immunology
Verified
Journal Article
Closed access
GMGonzalo Montero-Martín
Gonzalo Montero-Martín
KMKalyan C. Mallempati
Kalyan C. Mallempati
SGSridevi Gangavarapu
Sridevi Gangavarapu
FSFrancisco Sánchez-Gordo
Francisco Sánchez-Gordo
MHMaria J. Herrero-Mata
Maria J. Herrero-Mata
MFMarcelo A. Fernández-Viña
Marcelo A. Fernández-Viña

13 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HTHector Terán-Navarro
Hector Terán-Navarro
AZAndrea Zeoli
Andrea Zeoli
DSDavid Salines-Cuevas
David Salines-Cuevas
MMMarco Marradi
Marco Marradi
NMNoemi Montoya
Noemi Montoya
CACarmen Alvarez-Dominguez
Carmen Alvarez-Dominguez
This study presents proof of concept assays to validate gold nanoparticles loaded with the bacterial peptide 91–99 of the listeriolysin O toxin (GNP-LLO91–99 nanovaccines) as immunotherapy for bladder tumors. GNP-LLO91–99 nanovaccines showed adjuvant abilities as they induce maturation and activation of monocyte-derived dendritic cells (MoDCs) to functional antigen-presenting cells in healthy donors and patients with melanoma or bladder cancer (BC), promoting a Th1 cytokine pattern. GNP-LLO91–99 nanovaccines were also efficient dendritic cell inducers of immunogenic tumor death using different bladder and melanoma tumor cell lines. The establishment of a pre-clinical mice model of subcutaneous BC confirmed that a single dose of GNP-LLO91–99 nanovaccines reduced tumor burden 4.7-fold and stimulated systemic Th1-type immune responses. Proof of concept assays validated GNP-LLO91–99 nanovaccines as immunotherapy by comparison to anti-CTLA-4 or anti-PD-1 antibodies. In fact, GNP-LLO91–99 nanovaccines increased percentages of CD4+ and CD8+ T cells, B cells, and functional antigen-presenting DCs in tumor-infiltrated lymphocytes, while they reduced the levels of myeloid-derived suppressor cells (MDSC) and suppressor T cells (Treg). We conclude that GNP-LLO91–99 nanovaccines can work as monotherapies or combinatory immunotherapies with anti-CTLA-4 or anti-PD-1 antibodies for solid tumors with high T cell infiltration, such as bladder cancer or melanoma.

29 August 2020 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
José Luis HernándezJosé Luis Hernández
José Luis Hernández
CBCristina Baldeón
Cristina Baldeón
ALAna Elísabet López-Sundh
Ana Elísabet López-Sundh
J. Gonzalo Ocejo-VinyalsJ. Gonzalo Ocejo-Vinyals
J. Gonzalo Ocejo-Vinyals
RBRicardo Blanco
Ricardo Blanco
MGMarcos Antonio González-López
Marcos Antonio González-López
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with several comorbidities and vascular risk factors, such as dyslipidemia. The present study aimed to assess the possible associations between the lipid profile and atherogenic indexes and the severity of HS. Methods: This case-control study enrolled 78 HS patients and 62 healthy controls. Classic lipid profile and lipoprotein ratios, including the atherogenic index of plasma (AIP), were evaluated. The severity of HS was measured by the HS Physician Global Assessment (PGA). Results: HS-patients had lower serum total cholesterol and HDL-C levels and higher AIP than the control group. AIP was positively correlated to BMI, waist circumference, systolic and diastolic blood pressure, LDL-C, triglycerides, non-HDL-C, ApoB, HOMA, and hs-CRP and negatively to HDL-C and ApoA1. For the overall lipid profile, only AIP was related to a more severe HS (PGA ≥ 3) after controlling for age, sex, BMI, insulin resistance (IR), active smoking, and statin use (r = 0.268; p = 0.023). Multiple logistic regression adjusted for age, sex, BMI, IR, smoking status and statin use, showed that AIP ≥ 0.11 was significantly associated with the severity of HS (OR, 4.38; CI 95%, 1.09–17.50; p = 0.037). Conclusions: In conclusion, these results showed that AIP is significantly and independently associated with HS severity.